E.g., 06/18/2021
E.g., 06/18/2021
Title Category Credit Event Date Price
2020 Guideline: Advanced Prostate Cancer Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will review the important and newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive (HSPC) and Castration-Resistant Prostate Cancer (CRPC). This includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of M1 HSPC and non-metastatic MO CRPC. Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines.
Active Surveillance for Prostate Cancer (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Active surveillance is the recommended management for low-risk prostate cancer but is currently underutilized. This course includes five modules about active surveillance for prostate cancer, with a target audience of urologists, trainees and allied health professionals.
Addressing Disparities in Prostate Cancer Care Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Adjuvant Treatment in Bladder Cancer Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, this podcast episode is designed to improve the ability of the urologist to care for patients with bladder cancer. This activity aims to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects. The AUA Expert Exchange Podcast: Adjuvant Treatment in Bladder Cancer is designed to address a very specific learning opportunity and reach the urologist in an easy, flexible way with a smaller, targeted update.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 2 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Guidelines: Evaluation and Management of Localized Renal Masses: A Case-Based Approach Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will be interactive and case-based with imaging and videos that will lead into discussion of the most important AUA Guidelines recommendations. A primary focus will be surgical management and efforts to reduce the risk of complications, manage intraoperative complications, or optimize oncologic and functional outcomes. We will each take 3-5 minutes to highlight one recent major development in the field of kidney cancer.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:
Case-Based Discussion of AUA Non-Muscle Invasive Bladder Cancer Guidelines Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 Improved understanding and rationale for diagnostic and therapeutic interventions for non invasive and invasive bladder cancer; heightened awareness of multidisciplinary efforts necessary for optimal care; algorithms and sources of information to provide to staff and patients.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:AstellasAstraZenecaBristol-Myers SquibbGenentechMerckPfizer, Inc.Sanofi Genzyme
Case-Based Discussion: BCR and mHSPC & M0 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Early M1 CRPC Management & Advanced M1 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Chemo-ablation of Upper-Tract Urothelial Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will review management options for advanced prostate, bladder, and kidney cancer using evidence-based recommendations and guidelines. The trials and literature that helped to shape the guidelines will be included. Included will be older, more established therapies as well as newer treatments, including checkpoint inhibitors and antibody-drug conjugates. Learners will become familiar with not only the therapies and their mechanisms, but the data behind their approval as well as future directions.
Clinical Cases in Urology: Diagnosis and Treatment of Early Stage Testicular Cancer (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Cases in Urology guideline-based case scenarios were designed to help maximize the impact of the guidelines. This case will focus on the AUA Guideline, Diagnosis and Treatment of Early Stage Testicular Cancer. 
Common Dilemmas in Prostate Cancer Detection and Management Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 Course participants will:Optimally use PSA and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.Understand the principles of “risk-adapted” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores, and specific genetic mutations (eg BRCA1/2).Understand the roles of MRI, high frequency ultrasound and novel transperineal approaches to improve prostate biopsy.

Pages